Linked Life Data

6927603

Source:http://linkedlifedata.com/resource/pubmed/id/6927603

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6927603rdf:typepubmed:Citationlld:pubmed
pubmed-article:6927603lifeskim:mentionsumls-concept:C0162791lld:lifeskim
pubmed-article:6927603lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:6927603lifeskim:mentionsumls-concept:C0002556lld:lifeskim
pubmed-article:6927603lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:6927603pubmed:issue1lld:pubmed
pubmed-article:6927603pubmed:dateCreated1986-10-9lld:pubmed
pubmed-article:6927603pubmed:abstractTextThe rationale for pharmacokinetic monitoring of aminoglycosides is critically reviewed. Retrospective studies suggest that for optimal antibacterial effect, peak serum gentamicin concentrations should exceed 5 micrograms/ml, despite the fact that these concentrations are indirect measures of the concentration of drug at the site of infection. When quantitative results of antimicrobial susceptibility are known (e.g. MIC or MBC), limited data suggest that for most infections, the peak serum aminoglycoside concentration should exceed the minimum inhibitory concentration by four-fold. However, the optimal duration for which the serum concentration should exceed the MIC or MBC during each dosing interval and the detrimental effect of prolonged subinhibitory drug concentrations have not been evaluated. Furthermore, the immunological competence of the host and the pathogenicity of the infecting organism are important factors in achieving antibacterial response. Using serum creatinine as an indirect and relatively late indicator of nephrotoxicity, nadir gentamicin concentrations greater than 2 micrograms/ml may predispose patients to develop nephrotoxicity. In addition, recent information indicates that patients who accumulate excessive amounts of aminoglycosides in their tissues may be at higher risk for developing nephrotoxicity; these patients may be identified based on the extent of accumulation in their nadir concentrations with continuous dosing. The aminoglycosides diffuse into the inner ear fluids slowly and diffuse out with a half-life of decline in inner ear fluid concentrations slower than that in serum. High transient peak serum concentrations probably do not contribute significantly to the risk of ototoxicity. However, there is evidence from early clinical trials, studies using continuous infusions of aminoglycosides, and animal studies indicating that elevated nadir serum concentrations relate to the development of ototoxicity. There is considerable interpatient variability in the peak serum concentration, even when identical dosages based on body weight or surface area are administered. Similarly, the half-life for decline in serum concentrations is highly variable from patient to patient, even in patients with stable normal renal function. Absorption after intramuscular administration is reliable in most patients, although critically ill patients may experience erratic absorption. The distribution of aminoglycosides is altered in obese patients because of differences in extracellular fluid content between fat and other tissues.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:6927603pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:languageenglld:pubmed
pubmed-article:6927603pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:citationSubsetIMlld:pubmed
pubmed-article:6927603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6927603pubmed:statusMEDLINElld:pubmed
pubmed-article:6927603pubmed:issn0277-0008lld:pubmed
pubmed-article:6927603pubmed:authorpubmed-author:EvansW EWElld:pubmed
pubmed-article:6927603pubmed:authorpubmed-author:YeeG CGClld:pubmed
pubmed-article:6927603pubmed:issnTypePrintlld:pubmed
pubmed-article:6927603pubmed:volume1lld:pubmed
pubmed-article:6927603pubmed:ownerNLMlld:pubmed
pubmed-article:6927603pubmed:authorsCompleteYlld:pubmed
pubmed-article:6927603pubmed:pagination55-75lld:pubmed
pubmed-article:6927603pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:meshHeadingpubmed-meshheading:6927603-...lld:pubmed
pubmed-article:6927603pubmed:articleTitleReappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides.lld:pubmed
pubmed-article:6927603pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6927603pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:6927603pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6927603lld:pubmed